

- **Name:** **Richard L. Schilsky**
 - **Current Position & Affiliation:** **American Society of Clinical Oncology**
 - **Country:** **USA**
-

- **Educational Background:**

1971 B.A. (cum laude), University of Pennsylvania, Philadelphia, Pennsylvania
1975 M.D. (with honors), University of Chicago Pritzker School of Medicine, Chicago, Illinois

- **Professional Experience:**

1975 – 1976 Intern in Medicine, Parkland Memorial Hospital, Southwestern Medical School, Dallas, Texas
1976 – 1977 Resident in Medicine, Parkland Memorial Hospital, Southwestern Medical School, Dallas, Texas
1977 – 1980 Clinical Associate, Medicine Branch and Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland
1980 – 1981 Cancer Expert, Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland
1981 – 1984 Assistant Professor, Department of Internal Medicine, Division of Hematology and Medical Oncology, University of Missouri-Columbia School of Medicine; Head, Section of Hematology/Medical Oncology, Harry S. Truman Veterans Administration Hospital, Columbia, Missouri
1984 – 1986 Assistant Professor, Department of Medicine, The University of Chicago Pritzker School of Medicine; Joint Section of Hematology and Medical Oncology, The University of Chicago and Michael Reese Medical Centers
1985 – 2000 Member, Committee on Clinical Pharmacology, University of Chicago Pritzker School of Medicine
1986 – 1989 Associate Professor, Department of Medicine, The University of Chicago Pritzker School of Medicine; Joint Section of Hematology and Medical Oncology, The University of Chicago and Michael Reese Medical Centers
1986 – 1989 Associate Director, Joint Section of Hematology and Medical Oncology, The University of Chicago and Michael Reese Medical Centers
2
1989 – 1991 Associate Professor, Department of Medicine and Associate Director, Section of Hematology and Medical Oncology, The University of Chicago Pritzker School of Medicine
1991 – 2012 Professor, Department of Medicine, Section of Hematology-Oncology, The University of Chicago Pritzker School of Medicine (indefinite tenure)
1991 – 2012 Member, Cancer Research Center

1991 – 1999 Director, University of Chicago Cancer Research Center
1994 – 1999 Member, Committee on Cancer Biology
1999 – 2007 Associate Dean for Clinical Research, Biological Sciences Division and the Pritzker School of Medicine
2009 – 2012 Chief, Section of Hematology/Oncology, Department of Medicine
2009 – 2012 Deputy Director, University of Chicago Comprehensive Cancer Center
2013 – Professor emeritus, University of Chicago
2013 – 2016 Chief Medical Officer, American Society of Clinical Oncology
2016 - 2019 Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology
2020- Executive Vice President and Chief Medical Officer, American Society of Clinical Oncology

• **Professional Organizations:**

1980 – Member, American Society of Clinical Oncology
1981 – Member, American Association for Cancer Research
1981 – Member, American Association for the Advancement of Science
1982 – Member, American Federation For Clinical Research
1983 – Fellow, American College of Physicians
1983 – 1984 Senator, Midwest Section, AFCR
5
1983 – 1986 Councilor, Midwest Section, AFCR
1987 – 1988 Chairman-Elect, Midwest Section, AFCR
1988 – 1989 Chairman, Midwest Section, AFCR
1984 – Member, American Association for Cancer Education
1984 – Member, Central Society for Clinical Research
1984 – 2012 Member, New York Academy of Sciences
1988 – 2012 Member, Chicago Society of Internal Medicine
1988 – Member, American Society for Clinical Pharmacology and Therapeutics
1988 – Corresponding Member, European Society for Medical Oncology
1999 – 2012 Member, Association for Patient-Oriented Research
1999 – 2012 Fellow, Institute of Medicine of Chicago
2000 – 2006 Member, Drug Information Association
2002 – Member, International Society of Geriatric Oncology
2006 – Member, Society for Clinical Trials
2007 – Member, Illinois Medical Oncology Society
2009 – Member, Society for Translational Oncology
2010 – 2012 Member, Association of Specialty Professors

• **Main Scientific Publications:**

148. Cherny, N., de Vries, E., Dafni, U., Somerfield, M., McKernin, S., Piccart, M., Latino, N., Douillard, J., Schnipper, L., Garrett-Mayer, E., Bogaerts, J., Karlis, D., Zygoura, P., Vervita, K., Pentheroudakis, G., Tabernero, J., Zielinski, C., Wollins, D., Schilsky, RL: Comparative assessment of clinical benefit using the ESMO Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) and the ASCO Value Framework Net Health Benefit Score (ASCO-NHB v2). *J. Clin. Oncol.* DOI: 10.1200/JCO.18.00729, 37: 336-349, 2019.

149. Rodon, J., Soria, J-C., Berger, R., Miller, W., Rubin, E., Tsimberidou, A., Saintigny, P., Ackerstein, A., Brana, I., Loriot, Y., Afshar, M., Miller, V., Wunder, F., Bresson, C., Martini, J., Mendelsohn, J., Batist, G., Onn, A., Tabernero, J., Schilsky, RL., Lazar, V., Lee, J., Kuzrock, R: WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. *Nature Medicine* DOI: 10.1038/s41591-019-0424-4, 2019.

150. Van der Velden, D.L., Hoes, L.R., van der Wijngaart, H., van Berge Henegouwen, J.M., van Werkhoven, E., Roepman, P., Schilsky, R.L., de Leng, W.W.J., Huitema, A.D.R., Nuijen, B., Nederlof, P.M., van Herpen, C.M.L., de Groot, D.J.A., Devriese, L.A., Hoeben, A., de Jonge, M.J.A., Chalabi, M., Smit, E.F., de Langen, A.J., Mehra, N., Labots, M., Kapiteijn, S., Sleijfer, E., Verheul, H.M.W., Gelderblom, H., Voest, E.E: The Drug Rediscovery Protocol facilitates expanded use of existing anticancer drugs. *Nature.* 574: 127-131, 2019.

151. Al-Baghdadi, T, Halabi, S., Garrett-Mayer, E., Mangat, PK., Ahn, ER., Sahai, V, Alvarez, RH., Kim, ES., Yost, KJ., Guo, K., Rygiel, AL., Antonelli, KR., Butler, NL., Bruinooge, SS., Schilsky, RL: Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. *JCO Precision Oncology.* DOI: 10.1200/PO.19.00124. Published August 14, 2019.

152. Jones, R., Krenz, C., Gornick, M., Griffith, K., Spence, R., Bradbury, AR., De Vries, R., Hawley, ST., Hayward, RA., Zon, R., Bolte, S, Sadegi, N., Schilsky, RL, Jagsi, R.: Patient preferences regarding informed consent models for participation in a learning healthcare system for oncology *JCO Oncology Practice* (in press).

153. Garrett-Mayer, E., Kaltenbaugh, MW., Spence, R., Bruinooge, SS., Hudis, CA., Michels, D., Schilsky, RL: Discrepancies in financial self-disclosures and open payments reporting among authors of clinical research studies. *J. Clin. Oncol.* 38:480-487, 2019.

154. Jagsi, R., Griffith, K., Krenz, C., Jones, RD., Gornick, M., Spence, R., De Vries, R., Hawley, Sarah T., Hayward, R., Zon, Robin, B., Sage, Sadeghi, N., Schilsky, RL., Bradbury, AR: Effect of public deliberation on patient attitudes regard consent and data use in a